menu
    • menu
    [{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Slayback Pharma \/ Sandoz"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Azurity","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Enalapril Maleate","moa":"ACE","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Arbor Pharmaceuticals \/ Azurity","highestDevelopmentStatusID":"12","companyTruncated":"Arbor Pharmaceuticals \/ Azurity"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Ex-vivo Engineered Cell Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Pharmaceuticals \/ EdiGene","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Pharmaceuticals \/ EdiGene"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Norethisterone Acetate","moa":"Sperm penetration","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Slayback Pharma \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Slayback Pharma \/ Lupin"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Azurity Pharmaceuticals"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Slayback Pharma \/ Dr. Reddy\u2019s Laboratories"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole","moa":"ATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Azurity Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omeprazole","moa":"KATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Azurity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Azurity Pharmaceuticals"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Slayback Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Azurity Pharma \/ Azurity Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Azurity Pharma"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nimodipine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Azurity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nilotinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Azurity Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Azurity Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Azurity Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Azurity Pharma

    Menu

    Azurity Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AZURITY Wins FDA Approval for DANZITEN™ Tablets with No Mealtime Restrictions

                            Details : Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.

                            Product Name : Danziten

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 14, 2024

                            Lead Product(s) : Nilotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nimodipine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azurity Pharmaceuticals’ NYMALIZE® Oral Solution Approved by FDA

                            Details : Nymalize is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, approved for treating aneurysmal subarachnoid hemorrhage patients.

                            Product Name : Nymalize

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Nimodipine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azurity Announces FDA Approval Of Myhibbin™ Oral Suspension

                            Details : Myhibbin (mycophenolate mofetil) is an immunosuppressive agent acting as an inosine monophosphate dehydrogenase (IMPDH) inhibitor, indicated for preventing organ rejection in transplant patients.

                            Product Name : Myhibbin

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2024

                            Lead Product(s) : Mycophenolate Mofetil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Slayback Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Azurity Pharmaceuticals Acquires Slayback Pharma

                            Details : Through the acquisition, Azurity gains access to Slayback's pipeline including, Precedex (dexmedetomidine hydrochloride), an alpha2-adrenergic agonist with sedative properties used for short-term intravenous sedation.

                            Product Name : Precedex-Generic

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 27, 2023

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Slayback Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Brand Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Active Benign Gastric Ulcer ...

                            Details : KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients...

                            Product Name : Konvomep

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Brand Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep™ (Omeprazole and Sodium Bicarbonate for Ora...

                            Details : Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.

                            Product Name : Konvomep

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 02, 2022

                            Lead Product(s) : Omeprazole,Sodium Bicarbonate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Slayback Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Slayback Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in ...

                            Details : Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.

                            Product Name : Brimonidine Tartrate-Generic

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 29, 2022

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Slayback Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Slayback Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Enters Into a Licensing Agreement with Slayback Pharma to Obtain Exclusive Rights in ...

                            Details : Lumify® is an over-the-counter (OTC) eyedrop having Brimonidine Tartrate that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.

                            Product Name : Brimonidine Tartrate-Generic

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 29, 2022

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zonisamide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Azurity Pharmaceuticals, Inc. Announces FDA Approval of Zonisade™ (Zonisamide Oral Suspension)

                            Details : ZONISADE is first and only zonisamide formulation for oral liquid administration to be approved by FDA, as an adjunctive therapy for the treatment of partial seizures in adults and pediatric patients aged 16 years and older with epilepsy.

                            Product Name : Zonisade

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : Zonisamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Azurity Pharma

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zonisamide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Eton Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Announces FDA Approval of ZONISADE (Zonisamide Oral Suspension)

                            Details : Zonisade is the first and only zonisamide formulation for oral liquid administration to be approved by the US Food and Drug Administration as an adjunctive therapy for the treatment of partial seizures in adults and paediatric patients aged 16 years and ...

                            Product Name : Zonisade

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : Zonisamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Eton Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth